Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krakow, K.
Right arrow Articles by Sander, J.W.A.S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krakow, K.
Right arrow Articles by Sander, J.W.A.S.
Neurology 2001;56:1772-1774
© 2001 American Academy of Neurology
Brief Communications

Long-term continuation of levetiracetam in patients with refractory epilepsy

Karsten Krakow, MD;, M. Walker, MD;, C. Otoul and J.W.A.S. Sander, MD

From the Epilepsy Research Group, Department of Clinical Neurology, Institute of Neurology, University College London, and the National Society for Epilepsy (Drs. Krakow, Walker, and Sander), Chalfont St. Peter, UK; the Department of Neurology (Dr. Krakow), Goethe University, Frankfurt, Germany; and UCB S.A. (Dr. Otoul), Braine l’Alleud, Belgium.

Address correspondence and reprint requests to Dr. K. Krakow, Department of Neurology, Goethe University Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany; e-mail: k.krakow{at}em.uni-frankfurt.de

The long-term continuation (retention) rate, efficacy, and safety data of the new antiepileptic drug levetiracetam (LEV) was evaluated in all patients with epilepsy exposed to the drug during its developmental program (n = 1,422). The retention rate was estimated to be 60% after 1 year and 32% after 5 years. Thirty-nine percent (512/1,325) of patients had a seizure reduction of >=50%, and 13% (183/1,422) became seizure-free for at least 6 months. LEV seems an effective and well tolerated new antiepileptic drug.




This article has been cited by other articles:


Home page
 NeurologyHome page
T. A. Milligan, S. Hurwitz, and E. B. Bromfield
Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery
Neurology, August 26, 2008; 71(9): 665 - 669.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
J. Cavitt and M. Privitera
Levetiracetam Induces a Rapid and Sustained Reduction of Generalized Spike-Wave and Clinical Absence
Arch Neurol, October 1, 2004; 61(10): 1604 - 1607.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. Nicolson, S. A. Lewis, and D. F. Smith
A prospective analysis of the outcome of levetiracetam in clinical practice
Neurology, August 10, 2004; 63(3): 568 - 570.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. Coupez, R. Straetemans, G. Sehgal, A. Stockis, and Z.(S. Lu
Levetiracetam: Relative Bioavailability and Bioequivalence of a 10% Oral Solution (750 mg) and 750-mg Tablets
J. Clin. Pharmacol., December 1, 2003; 43(12): 1370 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Mula, M. R. Trimble, A. Yuen, R. S.N. Liu, and J. W.A.S. Sander
Psychiatric adverse events during levetiracetam therapy
Neurology, September 9, 2003; 61(5): 704 - 706.
[Abstract] [Full Text] [PDF]

Home page
 DTBHome page
{blacktriangledown}Levetiracetam - a new drug for epilepsy
DTB, April 1, 2002; 40(4): 30 - 32.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
S D Shorvon and K van Rijckevorsel
A new antiepileptic drug
J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 426 - 429.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.